Physician profile
Jaime A Tschen
NPI 1164527800
$4,436.28
in general payments reported to CMS, 2019-2025
24 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.60 · 2020: $329 · 2021: $561 · 2022: $593 · 2023: $883 · 2024: $905 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $670.94 | 2020-2025 | |
| Amgen INC. | $545.57 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $501.50 | 2021-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $439.88 | 2020-2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $425.46 | 2022-2025 | Adbry, Spevigo |
| Janssen Biotech, INC. | $313.19 | 2021-2025 | Tremfya, Stelara, Remicade |
| Vyne Pharmaceuticals INC. | $258.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $166.11 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.19 | 2022-2025 | Sotyktu |
| Incyte Corporation | $151.15 | 2022-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $146.95 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $124.98 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $108.99 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $85.35 | 2021-2023 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.35 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $54.83 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $45.48 | 2021-2025 | Dupixent |
| Dermira, INC. | $33.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.91 | 2022 | |
| Ucb, INC. | $30.91 | 2025 | Bimzelx |
| Kyowa Kirin, INC. | $21.56 | 2024 | Poteligeo |
| Organon LLC | $20.32 | 2025 | |
| Sun Pharmaceutical Industries INC. | $13.88 | 2025 | |
| Sebela Pharmaceuticals INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Tschen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.